Proteon Therapeutics, Inc is a privately held biopharmaceutical company developing novel, first-in-class pharmaceuticals to address the medical needs of patients with renal and vascular diseases. The company is leveraging a unique understanding of tissue remodeling to develop a pipeline of proprietary therapeutics. Proteon Therapeutics’ first drug candidate (PRT-201) is in development for the improvement of blood flow following vascular surgery procedures. The Company’s initial clinical focus is vascular access for hemodialysis and peripheral arterial disease (PAD).

Headlines

Proteon Founders Nicholas Franano, M.D. and William P. Whitaker, Esq. Named Ernst & Young Entrepreneur Of The Year® 2009 Award Winners in the Central Midwest Region Award Recognizes Entrepreneurial Excellence in Private Equity/Venture Capital Backed Category.

Proteon Therapeutics Completes Second Closing of Equity Financing: Raises Total Series B to $50 million. Proteon also receives orphan drug designation for its lead product candidate, PRT-201.

Proteon Therapeutics Completes $38M Equity Financing; Initiates Phase 1/2 Clinical Study of PRT-201 in Hemodialysis Patients and Signs Option Agreement with Major Pharmaceutical Company.

Proteon Therapeutics Presents New Data on PRT-201 at the Annual Meeting of the American Society of Nephrology in Philadelphia.

Proteon Therapeutics to Present New Data on PRT-201 at Transcatheter Cardiovascular Therapeutics (TCT) Annual Symposium in Washington, D.C., October 13, 2008.

Proteon Therapeutics, Inc., announced today it has received Food and Drug Administration (FDA) fast track designation for the development program for PRT-201.

Proteon Therapeutics appoints Gregory D. Phelps, a seasoned biopharmaceutical executive, to the Company's Board of Directors.

Proteon Therapeutics, Inc., announced today that a key patent has been issued by the European Patent Office.

Proteon Therapeutics to Present at Annual Meeting of American Society of Nephrology in San Francisco on November 2, 2007

Proteon Therapeutics completes $12 million financing and hires CFO

Proteon Therapeutics receives second issued U.S. patent broadly covering elastase vasodilation

Proteon Therapeutics adds experienced research and drug development talent to its team

EDC of Kansas City announces creation of “Kansas City Biotechnology Center”

Proteon Therapeutics receives issued U.S. patent broadly covering new method of artery and vein dilation

Proteon Therapeutics selects QSV Biologicals, Ltd for PRT-201 manufacturing

Proteon Therapeutics hires veteran biotechnology executive as CEO

Proteon Therapeutics, Inc. closes $19M in Series A financing